Icecure Medical Ltd
ICCM0.675USD
+0.010+1.52%
收盤 12/19, 16:00（美東）報價延遲15分鐘
46.54M總市值
虧損本益比TTM
關於 Icecure Medical Ltd 公司
Icecure Medical Ltd is an Israel-based company that is engaged in the healthcare sector. The Company operates as commercial stage medical device company focusing on the research, development and marketing of cryoablation systems, disposables and technologies based on liquid nitrogen, or LN2, for treating tumors. Cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in breast, lungs, kidneys, bones and other indications. Company's lead product is ProSense system, a single probe system, but in addition the Company developed an additional multi probe system that is expected to have the ability to freeze several tumors simultaneously or larger tumors, named MultiSense system, which has not yet been commercialized.
Icecure Medical Ltd簡介
公司代碼ICCM
公司名稱Icecure Medical Ltd
上市日期Feb 02, 2011
CEOShamir (Eyal)
員工數量64
證券類型Ordinary Share
年結日Feb 02
公司地址7 Ha'eshel St.
城市CAESAREA
上市交易所NASDAQ OMX - NASDAQ BASIC
國家Israel
郵編3079504
電話97246230333
網址https://icecure-medical.com/
公司代碼ICCM
上市日期Feb 02, 2011
CEOShamir (Eyal)
Icecure Medical Ltd公司高管
名稱
名稱/職務
職務
持股
持股變動
Mr. Eyal Shamir
Mr. Eyal Shamir
Chief Executive Officer, Director
Chief Executive Officer, Director
590.31K
+13.38%
Mr. Ronen Tsimerman
Mr. Ronen Tsimerman
Vice President - Finance, Vice President - Operations
Vice President - Finance, Vice President - Operations
355.08K
+15.46%
Mr. Naum Muchnik
Mr. Naum Muchnik
Vice President - Research & Development
Vice President - Research & Development
140.42K
+33.36%
Mr. Oded Tamir
Mr. Oded Tamir
External Director
External Director
20.00K
+100.00%
Ms. Elisabeth Sadka
Ms. Elisabeth Sadka
Vice President-Clinics, Regulations and Quality Assurance
Vice President-Clinics, Regulations and Quality Assurance
--
--
Ms. Tlalit Bussi Tel-Tzure
Ms. Tlalit Bussi Tel-Tzure
Vice President - Business Development & Marketing
Vice President - Business Development & Marketing
--
--
Ms. Sharon Levita
Ms. Sharon Levita
External Director
External Director
--
--
Mr. Doron Birger
Mr. Doron Birger
Independent Director
Independent Director
--
--
Mr. Yaacov Goldman
Mr. Yaacov Goldman
External Director
External Director
--
--
Mr. Ron Abraham Mayron
Mr. Ron Abraham Mayron
Chairman of the Board
Chairman of the Board
--
--
名稱
名稱/職務
職務
持股
持股變動
Mr. Eyal Shamir
Mr. Eyal Shamir
Chief Executive Officer, Director
Chief Executive Officer, Director
590.31K
+13.38%
Mr. Ronen Tsimerman
Mr. Ronen Tsimerman
Vice President - Finance, Vice President - Operations
Vice President - Finance, Vice President - Operations
355.08K
+15.46%
Mr. Naum Muchnik
Mr. Naum Muchnik
Vice President - Research & Development
Vice President - Research & Development
140.42K
+33.36%
Mr. Oded Tamir
Mr. Oded Tamir
External Director
External Director
20.00K
+100.00%
Ms. Elisabeth Sadka
Ms. Elisabeth Sadka
Vice President-Clinics, Regulations and Quality Assurance
Vice President-Clinics, Regulations and Quality Assurance
--
--
Ms. Tlalit Bussi Tel-Tzure
Ms. Tlalit Bussi Tel-Tzure
Vice President - Business Development & Marketing
Vice President - Business Development & Marketing
--
--
收入明細
單位: USD更新時間: 10月6日 週一
單位: USD更新時間: 10月6日 週一
FY2024
FY2023
FY2022
FY2021
FY2020
由於公司未披露，未能獲取相關數據
地區USD
名稱
營收
佔比
Other
1.46M
44.24%
United States
870.00K
26.44%
Japan
481.00K
14.62%
India
413.00K
12.55%
China
41.00K
1.25%
Israel
30.00K
0.91%
業務
地區
由於公司未披露，未能獲取相關數據
股東統計
更新時間: 11月17日 週一
更新時間: 11月17日 週一
持股股東
股東類型
持股股東
持股股東
佔比
Haixiang (Li)
37.48%
Shamir (Eyal)
0.86%
Tsimerman (Ronen)
0.51%
Mayron (Ron)
0.40%
Tel-Tzure (Tlalit Bussi)
0.28%
其他
60.47%
持股股東
持股股東
佔比
Haixiang (Li)
37.48%
Shamir (Eyal)
0.86%
Tsimerman (Ronen)
0.51%
Mayron (Ron)
0.40%
Tel-Tzure (Tlalit Bussi)
0.28%
其他
60.47%
股東類型
持股股東
佔比
Individual Investor
40.42%
Investment Advisor
0.19%
Hedge Fund
0.13%
Investment Advisor/Hedge Fund
0.06%
Research Firm
0.02%
Venture Capital
0.02%
其他
59.16%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
33
241.02K
0.35%
-53.58K
2025Q2
45
28.04M
40.84%
+56.20K
2025Q1
44
28.01M
47.78%
-9.18K
2024Q4
41
27.61M
48.82%
+489.62K
2024Q3
42
27.95M
49.54%
-2.17M
2024Q2
41
27.48M
56.81%
+3.00M
2024Q1
39
27.22M
56.29%
+2.63M
2023Q4
40
21.73M
47.63%
-6.82M
2023Q3
37
21.68M
47.52%
-6.84M
2023Q2
36
21.65M
47.45%
-6.97M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Haixiang (Li)
25.85M
37.65%
--
--
Dec 31, 2024
Shamir (Eyal)
590.31K
0.86%
+69.67K
+13.38%
Mar 24, 2025
Tsimerman (Ronen)
355.08K
0.52%
+47.55K
+15.46%
Mar 24, 2025
Mayron (Ron)
278.02K
0.41%
+55.45K
+24.91%
Mar 24, 2025
Tel-Tzure (Tlalit Bussi)
191.81K
0.28%
+35.32K
+22.57%
Mar 24, 2025
Levav (Shay)
141.86K
0.21%
+37.69K
+36.18%
Mar 24, 2025
Muchnik (Naum)
140.42K
0.2%
+35.13K
+33.36%
Mar 24, 2025
Huang (Yang)
113.44K
0.17%
+40.12K
+54.72%
Mar 24, 2025
Dotan (Merav Nir)
88.94K
0.13%
+30.84K
+53.09%
Mar 24, 2025
Malik (Galit)
79.67K
0.12%
+23.32K
+41.40%
Mar 24, 2025
查看更多
持股ETF
機構名稱
佔比
暫無數據
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
常見問題
Icecure Medical Ltd的前五大股東是誰？
Icecure Medical Ltd的前五大股東如下：
Haixiang (Li)持有股份：25.85M佔總股份比例：37.65%。
Shamir (Eyal)持有股份：590.31K佔總股份比例：0.86%。
Tsimerman (Ronen)持有股份：355.08K佔總股份比例：0.52%。
Mayron (Ron)持有股份：278.02K佔總股份比例：0.41%。
Tel-Tzure (Tlalit Bussi)持有股份：191.81K佔總股份比例：0.28%。
Haixiang (Li)持有股份：25.85M佔總股份比例：37.65%。
Shamir (Eyal)持有股份：590.31K佔總股份比例：0.86%。
Tsimerman (Ronen)持有股份：355.08K佔總股份比例：0.52%。
Mayron (Ron)持有股份：278.02K佔總股份比例：0.41%。
Tel-Tzure (Tlalit Bussi)持有股份：191.81K佔總股份比例：0.28%。
Icecure Medical Ltd的前三大股東類型是什麼？
Icecure Medical Ltd 的前三大股東類型分別是：
Haixiang (Li)
Shamir (Eyal)
Tsimerman (Ronen)
Haixiang (Li)
Shamir (Eyal)
Tsimerman (Ronen)
有多少機構持有Icecure Medical Ltd(ICCM)的股份？
截至2025Q3，共有33家機構持有Icecure Medical Ltd的股份，合計持有的股份價值約為241.02K，占公司總股份的0.35% 。與2025Q2相比，機構持股有所增加，增幅為-40.49%。
哪個業務部門對Icecure Medical Ltd的收入貢獻最大？
在FY2024，--業務部門對Icecure Medical Ltd的收入貢獻最大，創收--，占總收入的--% 。
